arrow_back Back Filing freshness 40-F FY 2025 SEC EDGAR

BIOHARVEST SCIENCES INC.

BHST
$1.42 ▼ -0.18 (-11.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Bearish
auto_awesome

Analytical Summary

BIOHARVEST SCIENCES INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth 37.0% ↘
Op. Margin -16.2% ↗
ROIC -21.8% ↗
FCF / Share —
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity 0.01
info Valuation on last close. End-of-day price, Nov 5, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$34.51M
↑ +37.0% —
Net Income Profit after all expenses
$-11.13M
↑ +13.8% —
Operating Margin Operating profit as % of sales
-16.2%
↑ +41.8% 11th
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
9
Returns
18
Financial Health
94
Cash Quality ↑
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 3 years · 3 quarters